Rimonabant

利莫那班

Report date: 2026/05/26 20:00:28
NME

Base Information

Drug NameRimonabant
Drug Alias NameRimonabantum利莫纳班ZimultiAcompliaRimoslim +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCannabinoid CB1 receptor antagonists
TargetsCannabinoid CB1 receptor
Therapy Area/IndicationsSchizophreniaFeeding and Eating DisordersSmoking Cessation +[20] 
Global Approved IndicationsObesity
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2006/06/19
Country/TerritoryCzechiaBelgiumBulgaria +[52] 
CombinationsNo
Global Highest StatusWithdrawn
Highest Status in ChinaDiscontinued
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSanofi AventisWeill Medical College of Cornell UniversityNational Institute On Alcohol Abuse And Alcoholism +[7] 
Active IndicationsN/A
Inactive IndicationsSchizophreniaFeeding and Eating DisordersSmoking Cessation +[20] 

Other Information

ATC CodeA08AX01
Related LinksWikipediaDrugBankKEGG